UCL Confidence in Concept 2013

Lead Research Organisation: University College London

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
 
Description Day - TIPS microparticles
Amount £250,000 (GBP)
Organisation AGA Nanotech Ltd 
Start  
 
Description Eisai Funding Kettler project
Amount £314,480 (GBP)
Organisation Eisai Ltd 
Sector Private
Country Japan
Start 09/2016 
End 12/2018
 
Description Gamma Healthcare - Day
Amount £198,000 (GBP)
Organisation Gamma Healthcare 
Sector Private
Country Unknown
Start 07/2015 
End 07/2016
 
Description LiDo Studentship Award -O'Brien
Amount £79,967 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
 
Description MRC Project Grant, Alastair O'Brien
Amount £460,940 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 08/2020
 
Description PharmAlliance, Mazzon
Amount £20,000 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 01/2016 
End 09/2016
 
Description UCL Technology Fund - Fish
Amount £70,000 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start  
 
Description UCL Technology Fund - Gaspar
Amount £1,000,000 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start  
 
Description UCL Technology Fund, Fish
Amount £75,000 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start 01/2016 
End 12/2016
 
Description UCLH BRC (SBC) grant - Day
Amount £140,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start  
 
Description Wellcome Trust Clinical Training Fellopwship - O'brien/George
Amount £273,288 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Research Training Fellowship
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
End 09/2018
 
Description Gale CiC Collaboration with GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Project proposal around the development of notch pathway modulators in the treatment of hearing loss. Project team provides theoretical, technical and practical disease biology expertise.
Collaborator Contribution In vitro compound screening and provision of modulator compounds
Impact Project completed disproving published literature data. The collaboration continues through the appointment of Rick Cousins (GSK) as a visiting professor to UCL.
Start Year 2015
 
Description Holmes CiC collaboration with Evotec 
Organisation Evotec
Country Germany 
Sector Private 
PI Contribution Developed project proposal and plan. Provided theoretical and practical disease expertise.
Collaborator Contribution Provided high quality primary screening, medicinal chemistry and xray crystallography
Impact Collaboration led to the development of a Wellcome Trust SDDI application that had to be withdrawn at the full stage due to illness. The project team is seeking alternative approaches to exploiting the data package generated. Multi-disciplinary - Chemistry, cheminformatics, biology, structural biology, clinical.
Start Year 2015
 
Description Mookerjee CiC collaboration with Medimmune 
Organisation MedImmune
Country United States 
Sector Private 
PI Contribution Development of research project proposal and plan. Disease and biology expertise.
Collaborator Contribution Generation and scaled up preparation of a key rat isoform of the LCAT protein needed in the project.
Impact Agreement with Medimmune to supply protein
Start Year 2015
 
Description Nathwani CiC collaboration with Puridify 
Organisation Puridify
Country United Kingdom 
Sector Private 
PI Contribution Development of the project proposal and plan. Theoretical, technical and practical biological and disease expertise.
Collaborator Contribution Technical expertise in the production and purification of AAV vectors
Impact Too early to be specific
Start Year 2015
 
Title Angiogenic Factors 
Description The disclosure relates to methods for obtaining angiogenic factors, as well as to methods of treating cardiovascular disease and methods for stimulating angiogenesis. 
IP Reference US2018028570 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact none to date
 
Title Muscle conditioning device 
Description The present invention relates to a muscle conditioning device comprising one or more implantable bodies and an actuator, where in use, the implantable bodies are magnetically coupled to the actuator and are resiliently positionable to administer mechanical strain to the muscle on operation of the actuator. It also relates to individual elements of the device; to compositions and kits thereof; and to uses of and methods involving the device. 
IP Reference WO2014091182 
Protection Patent application published
Year Protection Granted 2014
Licensed No
Impact Too early
 
Title QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS 
Description The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia: 
IP Reference WO2016034512 
Protection Patent application published
Year Protection Granted 2016
Licensed No
Impact too early
 
Title THERAPEUTIC AGENTS AND DELIVERY WITH MICROSPHERES 
Description TIPS loaded with therapeutic entities 
IP Reference EP3089738 
Protection Patent application published
Year Protection Granted 2016
Licensed No
Impact none to date
 
Title THERAPEUTIC AGENTS AND DELIVERY WITH MICROSPHERES 
Description The invention relates to methods for attaching therapeutic agents to structures produced by thermally induced phase separation as well as methods for coating devices and producing multi-layered microspheres. 
IP Reference WO2015097464 
Protection Patent application published
Year Protection Granted 2015
Licensed No
Impact none to date
 
Title TREATMENT 
Description The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient. 
IP Reference US2017173184 
Protection Patent application published
Year Protection Granted 2017
Licensed Yes
Impact Licensed to Orchard Tx
 
Title TREATMENT AND/OR PREVENTION OF LYSOSOMAL STORAGE DISEASES 
Description The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient. 
IP Reference WO2017103612 
Protection Patent application published
Year Protection Granted 2017
Licensed Yes
Impact licensed to Orchard Tx
 
Company Name Orchard Therapeutics Ltd 
Description Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy Our mission is to translate results from pre-clinical and early clinical research into commercially approved gene therapies for patients around the world 
Year Established 2015 
Impact Currently have one program in clinical development aiming to submit for marketing approval 2018/19
Website http://orchard-tx.com/
 
Company Name Virology Research Services 
Description Virology Research Services was founded by scientists at University College London to share world-leading resources and expertise with industry and academia, aiming to help combat infectious diseases. Our focus is preclinical studies and viral biology, where we provide rigorous, original, and cost-effective solutions to the early stages of R&D. We help companies and academics explore new antiviral treatments, investigate the biology of viral infection, and test pathogen response to treatment. 
Year Established 2018 
Impact Virology Research Services (VRS) was awarded a £25k MRC Proximity to Discovery Industry Engagement Fund for knowledge exchange with The Native Antigen Company (TNAC, LINK), a group focused on the expression and purification of viral antigens, and of antibodies targeting viral proteins. Most antibodies against viral proteins, particularly for emerging viruses, tend to be well characterised in biochemical assays; however, a thorough characterisation for immunofluorescence (IF) is often lacking. This represents a concern for scientists interested in image-based applications, who may need to test and optimise several antibodies before identifying a suitable one. Making use of the extensive virology and imaging expertise at VRS, and of the state-of-the-art high-throughput and microscopy facilities at UCL, the aim was to develop high- and low- throughput protocols for different antibodies, validate their specificity across viruses of the same family, and generate informative pictures as a reference. This successful collaboration which resulted in a full characterisation of TNAC's Antibodies and has been reported on the companies website: https://thenativeantigencompany.com/new-immunofluorescence-data-for-flavivirus-antibodies/
Website http://virologyresearchservices.com/